Free Trial
NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Price, News & Analysis

Cytek Biosciences logo
$4.00 -0.10 (-2.44%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$4.00 0.00 (0.00%)
As of 03/28/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cytek Biosciences Stock (NASDAQ:CTKB)

Key Stats

Today's Range
$3.97
$4.12
50-Day Range
$4.00
$6.00
52-Week Range
$3.97
$7.63
Volume
644,511 shs
Average Volume
710,442 shs
Market Capitalization
$512.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.42
Consensus Rating
Hold

Company Overview

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Remove Ads

Cytek Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

CTKB MarketRank™: 

Cytek Biosciences scored higher than 27% of companies evaluated by MarketBeat, and ranked 815th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Cytek Biosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Cytek Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytek Biosciences is -49.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytek Biosciences is -49.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cytek Biosciences has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cytek Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    3.28% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently increased by 10.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cytek Biosciences does not currently pay a dividend.

  • Dividend Growth

    Cytek Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.28% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently increased by 10.43%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cytek Biosciences has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cytek Biosciences this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytek Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.60% of the stock of Cytek Biosciences is held by insiders.

  • Percentage Held by Institutions

    69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cytek Biosciences' insider trading history.
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CTKB Stock News Headlines

$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Cytek Biosciences sees FY25 revenue $204M-$212M, consensus $216.52M
See More Headlines

CTKB Stock Analysis - Frequently Asked Questions

Cytek Biosciences' stock was trading at $6.49 at the start of the year. Since then, CTKB stock has decreased by 38.4% and is now trading at $4.00.
View the best growth stocks for 2025 here
.

Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings results on Tuesday, November, 5th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.03. The business had revenue of $51.50 million for the quarter, compared to analysts' expectations of $50.63 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 2.58% and a negative net margin of 5.05%.

Cytek Biosciences' Board of Directors authorized a stock buyback program on Monday, December 30th 2024, which authorizes the company to buy back $50,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 5.9% of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its shares are undervalued.

Cytek Biosciences (CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

Top institutional investors of Cytek Biosciences include Vanguard Group Inc. (9.10%), Geode Capital Management LLC (2.05%), Dimensional Fund Advisors LP (1.42%) and Wellington Management Group LLP (1.18%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod and Jack Ball.
View institutional ownership trends
.

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY) and Humana (HUM).

Company Calendar

Last Earnings
11/05/2024
Today
3/29/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:CTKB
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.42
High Stock Price Target
$8.00
Low Stock Price Target
$5.25
Potential Upside/Downside
+60.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,150,000.00
Pretax Margin
-5.92%

Debt

Sales & Book Value

Annual Sales
$200.45 million
Cash Flow
$0.02 per share
Price / Cash Flow
206.16
Book Value
$2.90 per share
Price / Book
1.38

Miscellaneous

Free Float
116,445,000
Market Cap
$512.39 million
Optionable
Optionable
Beta
1.41
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CTKB) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners